Trial Profile
A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- 07 Nov 2023 Planned End Date changed from 1 Nov 2008 to 22 Oct 2024.
- 08 Dec 2015 Results of post hoc analysis presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 07 Jul 2014 Treatment table changed from expansion phase to salvage therapy, anti coagulants removed and thalidomide added, design changed from open to double blind and official title changed accordingly.